Argo Blockchain
ARBK
Strategy
MSTR
BTCS Inc
BTCS
Canaan
CAN
Bit Origin
BTOG
US Stock MarketDetailed Quotes
FEMY Femasys
- 1.5900
- +0.2100+15.22%
Close Feb 14 16:00 ET
- 1.6500
- +0.0600+3.77%
Post 19:59 ET
36.41MMarket Cap-1.96P/E (TTM)
1.6300High1.3800Low1.03MVolume1.3800Open1.3800Pre Close1.59MTurnover4.87%Turnover RatioLossP/E (Static)22.90MShares2.400052wk High6.09P/B33.71MFloat Cap0.860052wk Low--Dividend TTM21.20MShs Float13.7500Historical High--Div YieldTTM18.12%Amplitude0.2479Historical Low1.5340Avg Price1Lot Size
Trending Stocks
U.S. Crypto Concept Stocks U.S. Crypto Concept Stocks
Companies involved in the creation, trade, and services of digital forms of money.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S. Crypto Concept Stocks, ranked from highest to lowest based on real-time market data. Companies involved in the creation, trade, and services of digital forms of money.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S. Crypto Concept Stocks, ranked from highest to lowest based on real-time market data.
Femasys Stock Forum
Femasys Announces UK Regulatory Approvals for FemaSeed® for Female Infertility Treatment and Two Diagnostic Devices
Tuesday, 11th February at 9:00 am
ATLANTA, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Femasys Inc., (NASDAQ: FEMY), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive, accessible in-office therapeutic and diagnostic products, announces the receipt of the Medicines & Healthcare products R...
Femasys -Israeli Regulatory Approvals for Femaseed for Female Infertility Treatment and Two Diagnostic Devices
Femasys Announces Israeli Regulatory Approvals for FemaSeed® for Female Infertility Treatment and Two Diagnostic Devices
Tuesday, 4th February at 9:00 am
ATLANTA, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Femasys Inc., (NASDAQ: FEMY), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive, accessible in-office therapeutic and diagnostic products, announces the receipt of the Israeli Medical Device Divisi...
Femasys Announces Notices of Intention to Grant for Two New European Patent Applications Covering Use of FemBloc Permanent Birth Control
Thursday, 30th January at 8:30 am
ATLANTA, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Femasys Inc., (NASDAQ: FEMY), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive, accessible in-office therapeutic and diagnostic products, announces the European Patent Office ("EP...
just
Femasys Announces Notice of Allowance for New U.S. Patent Application Covering Use of Femaseed® for Female Infertility Treatment
Femasys Announces Partnership With Hrc Fertility, Esteemed Conglomerate Provider of Fertility Services in Western U.S., to Offer Femaseed
Femasys Announces Partnership with HRC Fertility, Esteemed Conglomerate Provider of Fertility Services in Western U.S., to Offer FemaSeed
Femasys Inc., a leading biomedical company, has filed an amended Form 8-K/A with the SEC to correct previously reported dates. The amendment, dated November 12, 2024, rectifies the 'Date of Report' and related references from August 12, 2024, to the correct date of November 12, 2024. Alongside this administrative correction, Femasys announced its financial results for the third quarter ended September 30, 2024.
The company reported a significant increase in sales, primari...
No comment yet